Buscapina FEM 20mg 400mg 10 Pills, Butilhioscina/Ibuprofeno
THERAPEUTIC INDICATIONS: Anti-spasmodic, analgesic. Spasmodic pain, i.e. colic biliary tract and urogenital tract, primary dysmenorrhea.
Contraindications: Buscopan FEM ® is contraindicated in patients with: hypersensitivity to ibuprofen or the N-Butylscopolamine bromide, gastric or duodenal ulcer, history of nasal polyps, angioedema and bronchospasm induced by aspirin and other NSAIDs, myasthenia gravis, megacolon and lactating women.
Do not administer for more than 3-5 days.
GENERAL PRECAUTIONS: Patients with asthma, hay fever or chronic infections of the respiratory tract may have symptoms of hypersensitivity to ibuprofen (intolerance to analgesics / analgesics-induced asthma).
At any time there may be a serious gastrointestinal toxicity such as bleeding, ulceration and perforation with or without warning in patients chronically treated with NSAIDs. Patients with a history of serious gastrointestinal events and other risk factors that are known to be associated with peptic ulcer disease, such as alcoholism, smoking, etc., may be at particular risk of developing peptic ulceration and bleeding. FEM Buscopan ® should be used with caution in the elderly because they do not seem to tolerate ulceration and bleeding as well as others.
Should also be given in patients with porphyria (abnormalities in the metabolism of heme pigment), with impaired hepatic or renal function, with heart disease and / or hypertension, with inflammatory bowel (Crohn's disease, ulcerative colitis), and before and after major surgery.
After use of ibuprofen has been reported blurry vision and reduced scotoma and / or changes in color vision. If a patient develops such complaints while taking FEM Buscopan ®, the drug should be discontinued and the patient should undergo an ophthalmologic examination including a test of the central visual field and color vision.
Ibuprofen, like other NSAIDs, can inhibit platelet aggregation. The effect is, however, quantitatively less and takes less than that observed in acetylsalicylic acid. Ibuprofen has been shown to prolong bleeding time (but within the normal range) in healthy people.
Because this prolonged bleeding effect may occur in exaggerated form in patients with hemostatic defects basic FEM Buscopan ® should be used cautiously in patients with defective intrinsic coagulation system in patients undergoing anticoagulation therapy.
Due to the potential risk of anticholinergic complications, should be given in patients prone to glaucoma and patients susceptible to intestinal or urinary obstruction in patients prone to arrhythmia.
Even if Buscopan FEM is used as prescribed, can affect the reactions so that the ability to drive or operate machinery may worsen. This occurs to a greater degree in combination with alcohol.
RESTRICTIONS OF USE DURING PREGNANCY AND LACTATION: During the first and second quarters, Buscopan ® FEM should be used only in exceptional situations and under medical supervision. Observe the usual precautions as for all drugs taken during pregnancy. During the third quarter should be noted that ibuprofen can prolong the delivery, increasing the risk of bleeding. Due to the known effects of NSAIDs on the fetal cardiovascular system (closure of the ductus arteriosus), should avoid using FEM Buscopan ® during the last period of pregnancy.
So far not established the safety of FEM Buscopan ® during lactation. From studies conducted with ibuprofen alone, it is known that very small amounts pass into breast milk. However, due to the limited nature of these studies and possible side effects of drugs that inhibit prostaglandins in the newborn, FEM Buscopan ® is not indicated during lactation.
DOSAGE AND ADMINISTRATION
Adults and children over 12 years: 1 tablet, 3 to 4 times a day.
The tablets should not be chewed and should be taken during or after a meal with copious amounts of liquid.
Tablets are not suitable for children under 12 years.
Name of medicine: Buscopan Fem
Comparable patent medicine: Buscapina Fem
Active ingredient: Butilhioscina/Ibuprofeno
Extended-release tablets: No
Lab: Boehringer Ingelheim, S. A. DE CV
Box with 10 pills
Made in: Mexico